Zhejiang Haisen Pharmaceutical Co (001367) Fair Value & Analysis
Healthcare · CN · Market cap 2.8B CNY
Fair value as of: Aug 8, 2026
From 26 valuation models · updated 2 days ago
Fair value updated Aug 8, 2026, revised from ¥19.00 to ¥18.13 (−4.6%) since Jul 21, 2026. Share price +1.2% over the past month.
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (¥11.91 to ¥24.53) leaves room in how you read the outcome.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 8, 2026.
How to read this chart
40‑month range ¥12.97 – ¥36.33 · fair‑value band ¥11.91 – ¥24.53 · the ¥19.12 price screens above the ¥18.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 8, 2026.
Analysis
Zhejiang Haisen Pharmaceutical Co (001367) currently trades at ¥19.12, while our model-based Fair Value estimate is ¥18.13, implying the stock looks roughly 5.2% fairly valued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Zhejiang Haisen Pharmaceutical Co generated revenue of 521M CNY at a net margin of 25.6%. Revenue declined 9.5% year over year. It earns a return on equity of 9.2%. The stock trades on a trailing P/E of 23.3. Fundamentals as of Aug 8, 2026
Our scenario range runs from ¥11.91 (bear case) to ¥24.53 (bull case); at ¥19.12, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -5%, 001367 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥16.73) versus Dividend Discount (¥1.73). Highest evidence: Residual Income (76).
Notify me when 001367 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 8, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally.
Full company description
Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for use as antilipemic agents, antipyretic analgesics, antidepressants, analgesics, antibacterial agents, histamine drugs, and anticonvulsants, as well as for anti-gastric ulcers, and digestive and cardiovascular applications. It also provides chemical products for use as paroxetine HCl and amikacin sulphate intermediates and food additives; and escitalopram oxalate tablets to treat depression and panic disorders under the Tezi brand. In addition, the company engages in the import and export of goods; trading; and medical research and experimental development activities. Zhejiang Haisen Pharmaceutical Co., Ltd. was incorporated in 1998 and is headquartered in Dongyang, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang Haisen Pharmaceutical Co reported revenue of ¥532M in FY2025 versus ¥389M in FY2021, a compound +8.2%/yr. Reported net income was ¥136M in FY2025, compounding +9.6%/yr from FY2021.
Watch 001367: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - General · 76 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 8, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €226.68 | -42% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
Compare Zhejiang Haisen Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zhejiang Haisen Pharmaceutical Co (001367) overvalued or undervalued?
What is the fair value of 001367?
What is the quality score of 001367?
What is the revenue of Zhejiang Haisen Pharmaceutical Co (001367)?
What is the net profit margin of 001367?
Does Zhejiang Haisen Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhejiang Haisen Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.